Publications by authors named "Maria Elisa Riva"
Article Synopsis
- The immune system in chronic myeloid leukemia (CML) patients is significantly weakened, affecting their ability to respond to tumors, but shows improvement following effective treatment with tyrosine kinase inhibitors like imatinib.
- A study analyzed gene expression of various immune mediators in 171 blood samples from CML patients over their first year on imatinib, comparing it with samples from healthy donors.
- Results indicated that most immune mediators initially declined but largely normalized over time, while also revealing different patterns in optimal versus non-optimal treatment responders.
Background: Ponatinib is a third-generation tyrosine-kinase inhibitor (TKI), indicated in patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML), who are resistant or intolerant to ≥2 prior TKIs, patients for whom subsequent treatment with imatinib is not appropriate, and patients who have a T315I mutation.
Patients And Methods: We aimed to evaluate outcomes of ponatinib treatment, including safety, with focus on cardiovascular toxicity, in real-world patients from Argentina. Data from patients with CP CML treated with ponatinib was retrospectively retrieved from 2013 to 2023 in 7 centers.